ABSTRACT
The withdrawal of cisapride from the market will present challenges for physicians treating patients with nocturnal heartburn, gastroparesis, and dyspepsia. However, alternatives to the drug exist, and it will continue to be available under a limited-access program for patients for whom other drug treatments fail.
- Copyright © 2000 The Cleveland Clinic Foundation. All Rights Reserved.